Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$411.22
+0.9%		$412.35
$288.00
▼
$447.03
$222.18B0.412.74 million shs108,873 shs
argenex SE stock logo
ARGX
argenex
$812.94
-0.7%		$960.50
$661.85
▼
$1,072.75
$50.87B0.44343,705 shs29,712 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$149.33
+1.5%		$144.71
$114.02
▼
$157.29
$184.73B0.316.80 million shs154,636 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$512.55
+1.8%		$521.18
$402.58
▼
$560.25
$129.48B0.281.36 million shs32,311 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-1.37%+0.04%+3.63%+12.12%+38.29%
argenex SE stock logo
ARGX
argenex
-11.83%-12.54%-18.71%-6.72%+2.46%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.17%-0.27%+0.31%+13.30%+24.40%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-0.47%-0.69%-4.85%+3.68%+19.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$411.22
+0.9%		$412.35
$288.00
▼
$447.03
$222.18B0.412.74 million shs108,873 shs
argenex SE stock logo
ARGX
argenex
$812.94
-0.7%		$960.50
$661.85
▼
$1,072.75
$50.87B0.44343,705 shs29,712 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$149.33
+1.5%		$144.71
$114.02
▼
$157.29
$184.73B0.316.80 million shs154,636 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$512.55
+1.8%		$521.18
$402.58
▼
$560.25
$129.48B0.281.36 million shs32,311 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-1.37%+0.04%+3.63%+12.12%+38.29%
argenex SE stock logo
ARGX
argenex
-11.83%-12.54%-18.71%-6.72%+2.46%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.17%-0.27%+0.31%+13.30%+24.40%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-0.47%-0.69%-4.85%+3.68%+19.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.30
Hold$388.29-5.58% Downside
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,152.5641.78% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$159.266.65% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$575.3912.26% Upside

Current Analyst Ratings Breakdown

Latest ARGX, AMGN, GILD, and VRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
argenex SE stock logo
ARGX
argenex
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$932.00 ➝ $823.00
10/8/2026
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$400.00 ➝ $430.00
10/8/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$570.00 ➝ $576.00
10/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$123.00 ➝ $126.00
10/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$155.00
10/7/2026
Amgen Inc. stock logo
AMGN
Amgen
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$362.00 ➝ $380.00
10/7/2026
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$362.00 ➝ $359.00
10/7/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$150.00 ➝ $158.00
10/7/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$160.00 ➝ $170.00
10/7/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$165.00 ➝ $163.00
10/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$400.00 ➝ $440.00
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B6.05$33.65 per share12.22$16.08 per share25.57
argenex SE stock logo
ARGX
argenex
$5.23B9.73$18.68 per share43.52$118.34 per share6.87
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.29$10.64 per share14.03$18.23 per share8.19
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.59B10.33$17.82 per share28.77$73.57 per share6.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0925.5416.782.9822.95%124.14%13.18%11/3/2026 (Estimated)
argenex SE stock logo
ARGX
argenex
$1.29B$26.0431.2321.660.9732.19%43.59%36.66%N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A15.11N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1829.6927.932.2235.00%23.09%16.72%11/2/2026 (Estimated)

Latest ARGX, AMGN, GILD, and VRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.78N/AN/AN/A$10.05 billionN/A
11/2/2026Q3 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.77N/AN/AN/A$3.41 billionN/A
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.14N/AN/AN/A$7.78 billionN/A
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.45%+8.27%62.65%14 Years
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.20%+3.04%N/A 10 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ARGX, AMGN, GILD, and VRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.24%9/15/20269/15/20269/29/2026
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
argenex SE stock logo
ARGX
argenex
60.32%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
argenex SE stock logo
ARGX
argenex
2.43%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.81 million253.30 millionOptionable

Recent News About These Companies

Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why
October 8 at 11:54 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/andrew-hill-investment-fund-sees-135958583.html
Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why
October 8 at 11:31 AM  |  insidermonkey.comhttps://www.insidermonkey.com/news/andrew-hill-investment-fund-sees-more-growth-ahead-for-vertex-vrtx-heres-why-1849525/
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
October 7 at 6:02 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-announce-third-quarter-2026-200000492.html
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
October 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999987/vertex-pharmaceuticals-incorporated-vrtx-is-attracting-investor-attention-here-is-what-you-should-know?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks_v1-2999987
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-incorporated-vrtx-attracting-120007627.html
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
October 4, 2026  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/04/amgen-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026/
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Crosses Above 200 Day Moving Average - Here's Why
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081583
Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vertex-pharmaceuticals-nasdaq-vrtx-share-price-crosses-above-two-hundred-day-moving-average-whats-next-2026-10-03/
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-vrtx-regeneron-regn-two-024009734.html
CRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026
October 2, 2026  |  quiverquant.comQ
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-stock-falls-210006610.html
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-2-other-top-220722974.html
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999228/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v2-2999228
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
October 1, 2026  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/01/axsome-therapeutics-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026/
The Top HealthTech Questions Landing on Our Desks
September 30, 2026  |  etftrends.comE
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950636-vertex-stock-still-too-much-emphasis-on-cf-supremacy-i-foresee-rating-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=f5a22054-2c3a-46c9-8d92-39aea9607e62
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/
2 Healthcare Stocks to Target This Week and 1 We Avoid
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/2-healthcare-stocks-target-week-103836911.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-vertex-pharmaceuticals-vrtx-kidney-003708108.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/could-vertex-pharmaceuticals-vrtxs-kidney-breakthrough-unlock-a-new-opportunity-for-maze-therapeutics-maze-1846012/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Amgen stock logo

Amgen NASDAQ:AMGN

$411.22 +3.78 (+0.93%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

argenex stock logo

argenex NASDAQ:ARGX

$812.94 -5.69 (-0.70%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$149.33 +2.23 (+1.52%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$512.55 +9.30 (+1.85%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas